Establishment Labs Narrows Q4 Loss to $0.09, Revenue Up 45% to $64.6M
Establishment Labs reported a Q4 2025 loss of $0.09 per share, outperforming consensus by $0.13 and narrowing from a $0.98 loss a year earlier. Revenue climbed 45% to $64.62 million, beating estimates by 0.18%.
1. Q4 Loss and Earnings Surprise
Establishment Labs posted an adjusted Q4 loss of $0.09 per share, significantly narrower than the $0.98 loss in Q4 2024 and $0.22 loss forecast by analysts, delivering a 59.1% positive earnings surprise. This marks the third earnings beat in four quarters, reflecting improving operational leverage and cost management.
2. Revenue Growth and Beat
Q4 revenue rose 45% year-over-year to $64.62 million, topping the $64.5 million consensus by 0.18%. Strong adoption of the company’s portfolio drove the jump, while shares have added 2.9% year-to-date versus a 0.1% decline in the S&P 500.
3. Outlook and Analyst Estimates
Consensus for Q1 2026 calls for a loss of $0.54 per share on $57.49 million in revenue, while full-year 2026 estimates stand at a $0.84 loss on $263.43 million in sales. The Medical Services industry ranks in the bottom 38% of Zacks industries, underscoring analysts’ caution as they monitor guidance revisions.